Healthcare / Pharmaceutical RetailersShanghai
$18.26
-0.60 (-3.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $724.4M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
17.9x
↓EV/EBITDA
5.3x
↓ROE
5.5%
↑Gross Margin
36.1%
↓Debt/Equity
1.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.9%
FCF CAGR
+35.7%
FCF margin
11.5%
FCF / Net income
6.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.92B · net income $148.1M · FCF $1.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.92B | $8.92B | $9.28B | $9.08B | $7.51B |
| Net Income | $148.1M | $148.1M | $128.1M | $414.4M | $374.3M |
| EBITDA | $1.14B | $1.14B | $1.15B | $1.39B | $1.15B |
| EPS | 1.00 | 1.00 | 0.83 | 2.68 | 2.47 |
| Gross Margin | 36.1% | 36.1% | 35.8% | 35.9% | 36.1% |
| Operating Margin | 4.8% | 4.8% | 3.9% | 7.4% | 7.8% |
| Net Margin | 1.7% | 1.7% | 1.4% | 4.6% | 5.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.60 | 1.60 | 1.55 | 1.29 | 1.14 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.03B | $1.03B | $241.1M | $724.4M | $409.9M |
| Returns | |||||
| ROE | 5.5% | 5.5% | 4.6% | 14.5% | 14.5% |
| Valuation | |||||
| P/E | 17.90 | 17.90 | 25.58 | 22.79 | 27.31 |
| EV/EBITDA | 5.35 | 5.35 | 5.95 | 8.82 | 10.62 |
| P/B | 1.01 | 1.01 | 1.17 | 3.30 | 3.95 |
| Growth & Yield | |||||
| Revenue Growth | -3.9% | -3.9% | 2.2% | 20.8% | — |
| EPS Growth | 20.5% | 20.5% | -69.0% | 8.6% | — |
| Dividend Yield | 5.8% | 5.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.5%
EPS terminal req.
$1.62
Spread vs growth
3.0%
5Y implied EPS CAGR
14.4%
EPS terminal req.
$1.96
Spread vs growth
6.1%
10Y implied EPS CAGR
12.2%
EPS terminal req.
$3.16
Spread vs growth
8.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.7%
Start / end P/E
26.7x → 18.3x
EPS bridge
0.83 → 1.00
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.